Please login to the form below

Not currently logged in
Email:
Password:

Pfizer 2014 guidance threatened by Celebrex competition

Court overturns key patent for osteoarthritis drug
Pfizer headquarters

Generic competition to Pfizer's osteoarthritis drug Celebrex will come sooner than expected in the US after a key patent was overturned in the courts.

Several generic pharma companies have been planning to launch copycat versions of Celebrex (celecoxib) in the US on May 30, when the basic patent on the active ingredient of the drug expires.

Last March, however, Pfizer was awarded an additional 18 months of market exclusivity for the blockbuster brand - extending through December 2015 - after a method-of-use patent previously quashed  in 2008 was reinstated.

Armed with the so-called 're-issue' patent Pfizer filed suit against the generic drugmakers - which include Teva, Mylan, Watson Labs, Lupin Pharma and Apotex - and the case was due to be heard in court from March 19.

Now, a federal court has invalidated the re-issue patent, clearing the way for the generic launches to proceed as planned. Pfizer said in a statement that it strongly disagreed with the decision and plans to pursue "all available remedies," including an immediate appeal.

Celebrex sales were a little over $2.9bn last year, with $1.9bn of that total coming from the US market. The drug is the company's fourth biggest seller, and analysts have predicted the early onset of generic competition could wipe around $1bn off sales this year.

Pfizer's recently-issued financial guidance for 2014 is based on a full year of Celebrex sales, according to chief financial officer Frank D'Amelio. The company had said it expected to record sales of between $49.2bn and $51.2bn this year, shy of the $51.6bn it recorded in 2013.

The early onset of generic competition to Celebrex comes after a torrid time for Pfizer in terms of patent losses, with cholesterol lowerer Lipitor (atorvastatin), gastrointestinal medicine Protonix (pantoprazole), Viagra (sildenafil) for erectile dysfunction and antipsychotic Geodon (ziprasidone) all going in the last two to three years.

In PMLiVE's Top Pharma List, which ranks pharma companies by global sales, Pfizer retained the top spot, although the lead over Novartis was significantly cut.

Article by
Phil Taylor

13th March 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
...
Can eLearning improve patient recruitment and retention?
Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....
How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...

Infographics